Recent progress in research and development indicates that a significant achievement has been made in delivering various innovative medicines that stand out in their respective classes. This success positions the company for substantial long-term value creation through diverse therapeutic approaches. Notably, favorable data has been observed in the advanced stages of development for treatments focusing on neuropsychiatric conditions, such as Osavampator and Direclidine. This progress signifies a promising outlook for the company and its potential impact on improving patient outcomes.